740 results on '"Boon, Thierry"'
Search Results
2. An Antigenic Peptide Produced by Peptide Splicing in the Proteasome
3. A Monoclonal Cytolytic T-Lymphocyte Response Observed in a Melanoma Patient Vaccinated with a Tumor-Specific Antigenic Peptide Encoded by Gene MAGE-3
4. Tumor Dormancy as a Result of Simple Competition between Tumor Cells and Cytolytic Effector Cells
5. The Activation of Human Gene MAGE-1 in Tumor Cells is Correlated with Genome-Wide Demethylation
6. Data from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
7. Supplementary Figure 5 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
8. Supplementary Figure 1 from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
9. Supplementary Figure 6 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
10. Supplementary Figure 4 from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
11. Supplementary Figure 2 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
12. Supplementary Table 1 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
13. Supplementary Figure 4 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
14. Supplementary Figure 2 from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
15. Supplementary Figure 3 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
16. Supplementary Table 1 from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
17. Data from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
18. Supplementary Figure Legends 1-6 from The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
19. Supplementary Table 2 from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
20. Supplementary Figure 3 from Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases
21. Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy
22. Characterization of Antigens Recognized by T Cells on Human Tumors
23. Cytotoxic T-Lymphocyte Clones from Different Patients Display Limited T-Cell-Receptor Variable-Region Gene Usage in HLA-A2-Restricted Recognition of the Melanoma Antigen Melan-A/MART-1
24. A Mutated Intron Sequence Codes for an Antigenic Peptide Recognized by Cytolytic T Lymphocytes on a Human Melanoma
25. Teratocarcinoma Cell Variants Rejected by Syngeneic Mice: Protection of Mice Immunized with these Variants against other Variants and against the Original Malignant Cell Line
26. Tumor Cell Variants Obtained by Mutagenesis of a Lewis Lung Carcinoma Cell Line: Immune Rejection by Syngeneic Mice
27. Identification of the MAGE-1 Gene Product by Monoclonal and Polyclonal Antibodies
28. Rejection by Syngeneic Mice of Cell Variants Obtained by Mutagenesis of a Malignant Teratocarcinoma Cell Line
29. Cytolytic T-Cell Clones against an Autologous Human Melanoma: Specificity Study and Definition of Three Antigens by Immunoselection
30. Immunogenic (tum-) Variants of Mouse Tumor P815: Cloning of the Gene of tum- Antigen P91A and Identification of the tum- Mutation
31. Protection against a Nonimmunogenic Mouse Leukemia by an Immunogenic Variant Obtained by Mutagenesis
32. Inactivation of Ribosomes in vitro by Colicin E 3
33. Inactivation of Ribosomes In Vitro by Colicin E 3 and cits Mechanism of Action
34. A Mechanism for Genetic Recombination Generating One Parent and One Recombinant
35. Restoring the Association of the T Cell Receptor with CD8 Reverses Anergy in Human Tumor-Infiltrating Lymphocytes
36. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44
37. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195–203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules
38. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors
39. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1
40. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells
41. Myc represses transcription through recruitment of DNA methyltransferase corepressor
42. CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation
43. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
44. Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes
45. Transient Down-regulation of DNMT1 Methyltransferase Leads to Activation and Stable Hypomethylation of MAGE-A1 in Melanoma Cells
46. Cell- and stage-specific expression of Mage genes during mouse spermatogenesis
47. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy
48. A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
49. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma
50. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.